Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-1-antitrypsin - CSL Behring

Drug Profile

Alpha-1-antitrypsin - CSL Behring

Alternative Names: AAT - CSL Behring; Alpha-1 proteinase inhibitor - CSL Behring; Alpha-antitrypsin - CSL Behring; API; API Inhale; CSL 964; Respreeza; Zemaira

Latest Information Update: 29 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; Nektar Therapeutics
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II/III Graft-versus-host disease

Most Recent Events

  • 19 Nov 2019 CSL Behring plans a phase III trial for Graft-versus-host disease in December 2019 (IV) (NCT04167514)
  • 25 Apr 2019 Ragistered for Alpha 1-antitrypsin deficiency in USA (IV, 4gm and 5gm vial)
  • 01 Feb 2019 Phase-II/III clinical trials in Graft-versus-host disease (In adolescents, In adults) in USA, Spain (IV) (NCT03805789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top